Genomes and Genes
Summary: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Publications286 found, 100 shown here
- Diagnosis of gastrointestinal stromal tumors: A consensus approachChristopher D M Fletcher
Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston MA 02115, USA
Hum Pathol 33:459-65. 2002....
- A 5-decade analysis of 13,715 carcinoid tumorsIrvin M Modlin
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520 8062, USA
Cancer 97:934-59. 2003....
- Gastroenteropancreatic neuroendocrine tumoursIrvin M Modlin
Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520 8062, USA
Lancet Oncol 9:61-72. 2008..Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics...
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsGeorge D Demetri
Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
N Engl J Med 347:472-80. 2002..Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...
- Gain-of-function mutations of c-kit in human gastrointestinal stromal tumorsS Hirota
Department of Pathology, Osaka University Medical School, Yamada oka 2 2, Suita 565, Japan
Science 279:577-80. 1998..GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34...
- PDGFRA activating mutations in gastrointestinal stromal tumorsMichael C Heinrich
Department of Medicine, Department of Pathology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR 97201, USA
Science 299:708-10. 2003..Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs...
- Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumorsSeiichi Hirota
Department of Pathology, Osaka University Medical School, Suita, Japan
Gastroenterology 125:660-7. 2003..We investigated the cause of GISTs without KIT mutations. Because GISTs apparently expressed platelet-derived growth factor receptor (PDGFR) alpha, we examined whether GISTs without KIT mutations had a mutation of PDGFR alpha...
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsD A Tuveson
MIT Cancer Center and Department of Biology, Cambridge, MA 02139, USA
Oncogene 20:5054-8. 2001..These cell-culture-based studies support an important role for c-KIT signaling in GIST and suggest therapeutic potential for STI571 in patients afflicted by this chemoresistant tumor...
- Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich
R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
J Clin Oncol 21:4342-9. 2003..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST...
- KIT activation is a ubiquitous feature of gastrointestinal stromal tumorsB P Rubin
Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
Cancer Res 61:8118-21. 2001..These studies underscore the role of KIT activation in GIST pathogenesis, and they suggest that activated KIT might represent a universal therapeutic target in GISTs...
- The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumorsIsis Gayed
Department of Nuclear Medicine, M D Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
J Nucl Med 45:17-21. 2004..Therefore, we compared the roles of (18)F-FDG PET and CT in staging and evaluation of early response to imatinib mesylate therapy in recurrent or metastatic GIST...
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialJaap Verweij
Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
Lancet 364:1127-34. 2004..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
- Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumorsUlrich Frank Pape
Department of Hepatology and Gastroenterology, Chariteé Campus Virchow Clinic, Berlin University of Medicine, Berlin, Germany
Cancer 113:256-65. 2008..In 2006, a new TNM classification system was proposed for the staging and grading of upper GEP NETs...
- The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classificationGunter Kloppel
Department of General Pathology, University of Kiel, Kiel, Germany
Ann N Y Acad Sci 1014:13-27. 2004..On the basis of localization and of various morphological and biological criteria, we distinguish between benign neuroendocrine tumors, tumors with uncertain malignant potential, and tumors showing low-grade and high-grade malignancy...
- A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practicesP W T Pisters
Department of Surgical Oncology, Sarcoma Research Center at the University of Texas MD Anderson Cancer Center, Houston, USA
Ann Oncol 22:2523-9. 2011..The objective of the study was to describe patterns of care of patients with gastrointestinal stromal tumors (GISTs) in the United States in the tyrosine kinase inhibitor (TKI) era...
- A guide for the diagnosis and management of gastrointestinal stromal cell tumorsPaul S Sepe
Beth Israel Deaconess Medical Center, Boston, MA, USA
Nat Rev Gastroenterol Hepatol 6:363-71. 2009..This Review provides a general overview of GISTs, with an emphasis on their endoscopic diagnosis, the management of localized disease, and the management of incidentally discovered GISTs...
- Dual roles for immunity in gastrointestinal cancersCristina Ferrone
Dana Farber Cancer Institute, 44 Binney St, Dana 520C, Boston, MA 02115, USA
J Clin Oncol 28:4045-51. 2010..Here, we discuss the dual roles of immunity in cancer development, focusing on gastrointestinal malignancies, given the depth of recent insights into the mechanisms underlying these tumors...
- Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CTTadashi Watabe
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka, Japan
Ann Nucl Med 26:222-7. 2012..The purpose of this study was to evaluate the intratumoral metabolic heterogeneity of F-18 FDG uptake on PET to determine if it might be helpful to discriminate between these tumors...
- Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinibR Tielen
Department of Surgical Oncology, Radboud University Nijmegen Medical Centre, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands
Eur J Surg Oncol 39:150-5. 2013..We report on a large cohort of locally advanced GIST patients who have been treated in four centres in the Netherlands specialized in the treatment of sarcomas...
- Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working GroupJanine Kalkmann
Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg Essen, Hufelandstrasse 55, 45122 Essen, Germany
Cancer Imaging 12:126-35. 2012..The management of patients with GIST receiving a targeted therapy requires a standardized algorithm for imaging and an appropriate response assessment with respect to changes in lesion size and density...
- Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma J Verweij
Department of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
Eur J Cancer 39:2006-11. 2003..Imatinib mesylate is well tolerated at a dose of 400 mg bid. This dose is active in patients with KIT-positive GIST, but patients with other STS subtypes unselected for a molecular target are unlikely to benefit...
- Adjuvant therapy in primary GIST: state-of-the-artP Reichardt
Interdisciplinary Oncology, Helios Klinikum Berlin Buch, Berlin, Germany
Ann Oncol 23:2776-81. 2012..The objectives of this European Expert Panel meeting were to describe the optimal management and best practice for the systemic adjuvant treatment of patients with primary GISTs...
- Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic siteCristina R Antonescu
Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
Clin Cancer Res 10:3282-90. 2004..We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors...
- Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinibO Dudeck
Department of Radiology, HELIOS Clinic Berlin Buch, Berlin, Germany
Ann Oncol 22:1828-33. 2011..Controversies exist about computed tomography (CT) response evaluation criteria for patients with gastrointestinal stromal tumor (GIST)...
- Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumoursValentina Ambrosini
Unità Operativa di Medicina Nucleare, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Padiglione 30, Via Massarenti 9, 40138, Bologna, Italy
Eur J Nucl Med Mol Imaging 35:1431-8. 2008..At present, there are no comparative studies investigating their role in NET...
- Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database studyM B Wallace
Digestive Disease Center, Medical University of South Carolina, USA
Gut 49:29-34. 2001..Better clinical prediction strategies are needed to identify patients with significant upper gastrointestinal pathology...
- Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosisPeter Vestergaard
The Osteoporosis Clinic, Department of Endocrinology and Internal Medicine MEA, Aarhus University Hospital THG, Denmark
Calcif Tissue Int 89:434-41. 2011..However, the association may not be causal as no dose-response or time relationship was present. For colon cancer, the decline with increasing alendronate dose may be due to a "healthy user" effect...
- Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parametersMartin B Niederle
Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria
Endocr Relat Cancer 17:909-18. 2010..7%) were grade 1, 31.2% grade 2 and 9.1% grade 3. NETs of the digestive tract are more common than previously reported; the majority show benign behaviour, are located in the stomach and are well differentiated. G3 tumours are very rare...
- Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinomaCosimo Durante
Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 94805 Villejuif Cedex, France
Endocr Relat Cancer 16:585-97. 2009..This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials...
- Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gutJonathan Strosberg
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33629, USA
Neuroendocrinology 89:471-6. 2009..Past analyses of survival suggest a trend towards improving longevity among patients with metastatic mid-gut NETs...
- Association between H-RAS T81C genetic polymorphism and gastrointestinal cancer risk: a population based case-control study in ChinaYongjing Zhang
Department of Epidemiology and Health Statistics, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, PR China
BMC Cancer 8:256. 2008..Therefore, we hypothesized that this polymorphisms in H-RAS could influence susceptibility to gastrointestinal cancer as well, and we conducted this study to test the hypothesis in Chinese population...
- The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liverRicha Jain
Department of Pathology, The Toronto General Hospital, University Health Network University of Toronto, Toronto, Ontario, Canada
Appl Immunohistochem Mol Morphol 18:9-15. 2010..It can also be used to highlight native ductules in the liver and helps separate conditions such as focal nodular hyperplasia from hepatic adenoma. The vast majority of adenocarcinomas in the GIT and pancreas are CK19 positive...
- State reduction for network intervention in probabilistic Boolean networksXiaoning Qian
Department of Computer Science and Engineering, University of South Florida, Tampa, FL 33620, USA
Bioinformatics 26:3098-104. 2010..A major obstacle for its application is the large state space of the underlying Markov chain, which poses a serious computational challenge. Hence, it is critical to reduce the model complexity of PBNs for practical applications...
- Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trendsShotaro Nakamura
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Cancer 97:2462-73. 2003..This study aimed to elucidate the clinicopathologic features of this disease and the influence of therapeutic modalities on the prognosis in Japanese patients..
- GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCRMark Kidd
Gastrointestinal Research Group, Yale University School of Medicine, New Haven, Connecticut, USA
Physiol Genomics 30:363-70. 2007....
- Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumoursA H G Davies
Institute of Liver Studies, Carcinoid Clinic, King s College Hospital, Denmark Hill, London SE5 9RS, UK
Eur J Cancer 42:477-84. 2006..The EORTC QLQ-NET21 provides a site-specific module to supplement the QLQ-C30 for patients with neuroendocrine tumours...
- Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivityMaria Debiec-Rychter
Laboratory for Cytogenetics and Molecular Genetics of Human Malignancies, Department of Human Genetics, Catholic University of Leuven, Belgium
J Pathol 202:430-8. 2004..While intragenic PDGFRA activating mutations are present in some of these tumours, the oncogenic events underlying the pathogenesis of the others remain unknown...
- Pathogenesis of adenocarcinoma in Peutz-Jeghers syndromeS B Gruber
Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor 48109, USA
Cancer Res 58:5267-70. 1998..Additional somatic mutational events underlie the progression of hamartomas to adenocarcinomas, and some of these somatic mutations are common to the later stages of tumor progression seen in the majority of colorectal carcinomas...
- Computed tomography in gastrointestinal stromal tumorsNadir Ghanem
Department of Diagnostic Radiology, University Hospital Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
Eur Radiol 13:1669-78. 2003....
- Inflammasomes in intestinal inflammation and cancerGrace Y Chen
Division of Hematology and Oncology, Department of Internal Medicine, and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, USA
Gastroenterology 141:1986-99. 2011....
- Perioperative immunonutrition for gastrointestinal cancer: a systematic review of randomized controlled trialsYan Zhang
Gansu Provincial Hospital, Donggang West Road No 204, Chengguan District, Lanzhou City, Gansu Province, China
Surg Oncol 21:e87-95. 2012..To improve the clinical outcome, immunonutrition (IN) was usually used in the patients undergoing elective gastrointestinal caner surgery. However, its effectiveness remains uncertain...
- Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)U Plockinger
Department of Hepatology and Gastroenterology, Interdisciplinary Center for Metabolism, Endocrinology, and Diabetes, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
Neuroendocrinology 80:394-424. 2004
- Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosisM Miettinen
Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
Virchows Arch 438:1-12. 2001..Angiosarcomas and metastatic melanomas, both of which are often KIT-positive, should not be confused with GISTs...
- Hepatic surgery for metastases from neuroendocrine tumorsJuan M Sarmiento
Division of Gastroenterologic and General Surgery, Mayo Clinic, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Surg Oncol Clin N Am 12:231-42. 2003..The best hope physicians can offer these patients is an extended survival period with minimal endocrine symptoms and decreased requirements of somatostatin analogs...
- Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spreadGuy J C Burkill
Department of Radiology, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, England
Radiology 226:527-32. 2003..To investigate and describe the anatomic distribution, imaging features, and pattern of metastatic spread of malignant gastrointestinal stromal tumors (GISTs)...
- Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 casesB Brenner
The Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Cancer 90:1720-6. 2004..Mixed tumour histology is common and may affect therapy. Surgery, combined with chemotherapy, should be considered for LD. The value of the VALSG system was implied and possible differences from small-cell lung cancer were noted...
- Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individualsPaul Lochhead
Gastrointestinal Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland
Gastroenterology 140:435-41. 2011..We set out to determine whether such an association exists in white individuals...
- Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumorsCristina R Antonescu
Department of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology Program, Sloan Kettering Institute, New York, New York, 10021, USA
Clin Cancer Res 9:3329-37. 2003..The impact of KIT mutation in other regions, such as the extracellular or kinase domains, is not well-defined and fewer than 30 cases have been published to date...
- KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in sizeChristopher L Corless
Department of Pathology, Division of Hematology Oncology, Oregon Health and Science University, Portland, 97201, USA
Am J Pathol 160:1567-72. 2002..The findings suggest that KIT mutations per se are of little prognostic importance in GISTs...
- Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effectsChristophe Borg
Department of Clinical Biology, Equipe de Recherche Mixte 0208, INSERM, Institut Gustave Roussy, Villejuif, France
J Clin Invest 114:379-88. 2004..These data point to a novel mode of antitumor action for Gleevec...
- Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumorsJohn Eriksson
Department of Surgery, University Hospital, SE 751 85 Uppsala, Sweden
World J Surg 32:930-8. 2008..However, it is not clear whether such therapy will provide symptom reduction or increased survival...
- PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumorsAtsushi Motegi
Department of Tumor Pathology, Graduate School of Medicine, Gunma University, Maebashi shi, Gunma, Japan
Pathol Int 55:106-12. 2005..The present study revealed that PKC theta is an immunohistochemically novel and useful marker for GIST, especially for GIST negative for KIT...
- Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 yearsH Nave
Clinic of Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany
Surgery 129:170-5. 2001..CONCLUSIONS: Surgery for metastatic carcinoid tumors may be curative or palliative, with a potential for cure in some cases and prolongation of survival and amelioration of symptoms in the majority of patients...
- Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvementXue Qin Yang
Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center and Hubei Key Laboratory on Tumor Biological Behaviors, Wuhan, 430071, China
Hepatogastroenterology 56:1388-94. 2009..Serum tumor markers (TMs) are frequently used in the diagnosis of GI cancer. This study was to assess value of C12 multi-tumor marker protein chip diagnostic system developed in China in GI cancer...
- A prospective study comparing endoscopy and EUS in the evaluation of GI subepithelial massesJoo Ha Hwang
Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, 98195, USA
Gastrointest Endosc 62:202-8. 2005..The purpose of this study is to prospectively evaluate the performance characteristics of endoscopy and EUS in the diagnosis of GI subepithelial masses...
- Gastrointestinal stromal tumors: biology and treatmentFlorence Duffaud
Service d Oncologie Medicale, CHU Timone Adultes, Marseille, France
Oncology 65:187-97. 2003..Additional follow-up is necessary. Glivec treatment of GIST is the first example of an efficient targeted treatment in a solid tumor...
- A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomasJonathan C Trent
Department of Sarcoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:2693-9. 2003..Patients with GIST were eligible regardless of prior therapy before imatinib was available...
- Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resectionPiotr Rutkowski
Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Cancer 117:4916-24. 2011....
- Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular geneticsMarkku Miettinen
Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
Pol J Pathol 54:3-24. 2003..Majority of these mutations are in-frame-deletions and missense mutations clustering in the 5'-end of juxtamembrane domain (exon 11). A rare mutation, an Ala502-Tyr503 duplication in exon 9, is specific for intestinal GISTs...
- Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
Oncogene 23:7780-90. 2004..These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated...
- Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumoursAntoine Italiano
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Eur J Cancer 48:3215-22. 2012..Data regarding the patterns and the mechanisms of deregulation of the insulin growth factor (IGF) pathway in adult and paediatric gastrointestinal stromal tumours (GISTs) are limited...
- Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot seriesT Rosch
Department of Internal Medicine II and Pathology, Technical University of Munich, Munich, Germany
Endoscopy 36:788-801. 2004....
- Lack of association of miR-146a rs2910164 polymorphism with gastrointestinal cancers: evidence from 10206 subjectsFang Wang
Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
PLoS ONE 7:e39623. 2012..Accordingly, we conducted a comprehensive literature search and a meta-analysis to clarify the association...
- Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patientsWen Chi Chou
Division of Hematology Oncology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, No 5 Fushing St, Kweishan Shiang, Taoyuan, Taiwan, ROC
Neuroendocrinology 95:344-50. 2012..To evaluate the significance of plasma chromogranin A (CgA) levels in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in terms of disease status and treatment responses...
- IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancersMohammad Reza Haghshenas
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
J Gastroenterol Hepatol 24:1119-22. 2009..Interleukin (IL)-18 level and association of its two promoter gene polymorphisms at -607 C/A and -137 G/C positions were investigated in Iranian patients with gastrointestinal (GI) cancers...
- Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumourYasuyuki Okamoto
Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Gut 61:392-401. 2012..Our aim was to establish epigenetic profiles associated with the malignant transformation of GISTs...
- The diagnosis and medical management of advanced neuroendocrine tumorsGregory A Kaltsas
Department of Endocrinology, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
Endocr Rev 25:458-511. 2004..Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival...
- Impact of endoscopic ultrasound for evaluation of submucosal lesions in gastrointestinal tractB Brand
Department of Interdisciplinary Endoscopy, University Hospital Eppendorf, Hamburg, Germany
Dig Liver Dis 34:290-7. 2002..Endoscopic ultrasound is widely used following endoscopy for evaluation of suspected submucosal lesions and may guide further management of patients...
- Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancerYue Hong Cui
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
J Dig Dis 10:118-23. 2009..To explore the polymorphism of thymidylate synthase (TS) gene and chemosensitivity of a 5-fluorouracil (5-FU)-containing regimen in metastatic colorectal and gastric cancer...
- Therapeutic options for gastrointestinal carcinoidsIrvin M Modlin
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520 8062, USA
Clin Gastroenterol Hepatol 4:526-47. 2006..The keystone of current therapy remains the long-acting somatostatin analogues that alleviate symptomatology and substantially improve quality of life with minimal adverse effects...
- NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristicsJohanna Andersson
Lundberg Laboratory for Cancer Research, Department of Pathology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
Am J Surg Pathol 29:1170-6. 2005..NF1-associated GIST are also phenotypically and genotypically distinct from sporadic GIST, indicating that different pathogenetic mechanisms are involved in their evolution...
- Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)George Papaxoinis
Second Department of Internal Medicine, Athens University, University General Hospital Attikon, Haidari, Greece
Leuk Lymphoma 47:2140-6. 2006..0001). The International Prognostic Index (IPI) for patients with aggressive lymphomas was prognostic only for DFS (79% for low-risk patients [IPI score 0 - 1] vs 49% for higher risk groups [IPI score >1] at 3-year, P = 0.0131)...
- Cruciferous vegetables, mushrooms, and gastrointestinal cancer risks in a multicenter, hospital-based case-control study in JapanMegumi Hara
Epidemiology and Biostatistics Division, National Cancer Center Research Institute East, Chiba, Japan
Nutr Cancer 46:138-47. 2003..These findings suggest that cruciferous vegetables decrease the risk of both stomach and colorectal cancer, and that mushrooms are associated with a decreased risk of stomach cancer...
- Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplementsG Bjelakovic
The Cochrane Hepato Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigs Hospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Aliment Pharmacol Ther 28:689-703. 2008..The evidence on whether antioxidant supplements prevent gastrointestinal cancers is contradictory...
- Development of Cryptosporidium parvum-induced gastrointestinal neoplasia in severe combined immunodeficiency (SCID) mice: severity of lesions is correlated with infection intensityGabriela Certad
Ecologie du Parasitisme EA3609 Université de Lille 2, IFR 142, Institut Pasteur de Lille, Lille, France
Am J Trop Med Hyg 82:257-65. 2010..Immunohistochemistry for Ki-67 staining indicated the neoplastic process associated to cryptosporidiosis, and evidenced the first immunohistochemical alterations at early stages of the process, even at 3 weeks PI...
- Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with ImatinibChandu M V de Silva
University Department of Pathology, Western Infirmary, Glasgow, G11 6NT, UK
Pathol Oncol Res 9:13-9. 2003..This review summarises recent advances in knowledge regarding the histogenesis, pathology, molecular biology, genetics and differential diagnosis of GISTs and the basis for the novel targeted cancer therapy with imatinib...
- Impact of chromogranin A measurement in the work-up of neuroendocrine tumorsE Baudin
Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France
Ann Oncol 12:S79-82. 2001..Both tumor burden and secretory activity should be taken into account when interpreting CgA results...
- Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumorsAmitabh Srivastava
Dartmouth Medical School, Dartmouth Hitchcock Medical Center Lebanon, NH, USA
Am J Surg Pathol 33:626-32. 2009..TTF-1 positivity was confined to pulmonary carcinoids in our study but was present in only about a third of cases. A panel of these 4 markers may be useful in predicting the primary site of metastatic WDNET...
- A functional NQO1 609C>T polymorphism and risk of gastrointestinal cancers: a meta-analysisHongping Yu
Department of Epidemiology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 7:e30566. 2012....
- A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignanciesU N Vaishampayan
Department of Internal Medicine, Division of Oncology, The Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
Int J Radiat Oncol Biol Phys 53:675-9. 2002..We report our clinical experience with 32 patients receiving concurrent irradiation and capecitabine...
- Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritisElizabeth Montgomery
Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
Am J Surg Pathol 26:1296-301. 2002..beta-Catenin staining identifies lesions that are, instead, mesenteric fibromatoses...
- Plasma chromogranin a in patients with inflammatory bowel diseaseValentina Sciola
Gastroenterology Unit II, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
Inflamm Bowel Dis 15:867-71. 2009..Therefore, we aimed to evaluate CgA levels and their possible relationship with clinical and biochemical disease activity indexes in 119 IBD patients...
- Alarm features and age for predicting upper gastrointestinal malignancy in Chinese patients with dyspepsia with high background prevalence of Helicobacter pylori infection and upper gastrointestinal malignancy: an endoscopic database review of 102,665 patYu Bai
Department of Gastroenterology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, China
Gut 59:722-8. 2010..The aim of the present study was to determine the diagnostic accuracy of alarm features in predicting upper GI malignancy by reviewing an endoscopic database consisting of >100,000 Chinese patients...
- Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature reviewG Damaj
Hopital Necker Enfants Malades, Paris, France
Ann Oncol 14:623-9. 2003..To describe better the clinical, biological, endoscopic and pathological presentations, as well as the outcome, of primary follicular lymphoma (FL) of the gastrointestinal (GI) tract...
- Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosisAnjali D Amarapurkar
Institute of Liver Studies and Carcinoid Clinic, King s College Hospital, Denmark Hill, London SE5 9RS, UK
Eur J Gastroenterol Hepatol 15:139-43. 2003..The MIB-1 antibody, which detects cell proliferative activity, has been shown to be a useful prognostic marker for a variety of neoplasms...
- Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancyG A J Fransen
Department of General Practice, Maastricht University, Maastricht, The Netherlands
Aliment Pharmacol Ther 20:1045-52. 2004..Usually alarming symptoms are used for this matter, but their diagnostic value is by no means clear...
- Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignanciesLinda M Velasquez
Bristol Myers Squibb Co, Princeton, New Jersey 08543, USA
J Nucl Med 50:1646-54. 2009....
- European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancerFlorian Lordick
National Centre for Tumour Diseases, Department of Medical Oncology, University of Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
Eur J Cancer 44:1807-19. 2008..This paper reviews the lectures and discussions held during this workshop and summarises the action points for the further investigation of metabolic imaging to guide treatment in gastrointestinal tumours...
- Occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract: a meta-analysisNicole M Gatto
ToxStrategies, Inc, Rancho Santa Margarita, CA, USA
Cancer Epidemiol 34:388-99. 2010..We conducted a systematic literature review and meta-analysis of oral cavity, esophageal, stomach, small intestine, colon, and rectal cancers among workers occupationally exposed to Cr(VI)...
- Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registryK A Gurney
Leukaemia Research Fund Centre for Clinical Epidemiology, University of Leeds, UK
Br J Cancer 79:1929-34. 1999..Overall, the incidence of gastrointestinal NHL significantly increased by 2.7% per annum and was limited to the population aged over 50 years in this series...
- Somatostatin receptor imaging for neuroendocrine tumorsWouter W de Herder
Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
Pituitary 9:243-8. 2006..However, a large variety of lesions in and around the pituitary region also express somatostatin receptors and, therefore, can be visualized by (111)In-pentetreotide scintigraphy...
- Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylatePiotr Rutkowski
Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
J Surg Oncol 93:304-11. 2006..The aim of the study was to analyze the surgical possibilities of unresectable and/or metastatic GIST CD117(+) patients during imatinib treatment...
- Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumorsTae Won Kim
Section of Oncology Hematology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Clin Cancer Res 10:3076-81. 2004..Constitutive mutational activation of c-kit has been found to be associated with the pathogenesis of gastrointestinal stromal tumors (GISTs). The prognostic significance of c-kit mutations, however, is still controversial...
- Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter StudyMaria Chiara Zatelli
Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy
Endocr Relat Cancer 14:473-82. 2007....
- The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) studyA B R Thomson
University of Alberta, Edmonton, Alberta, Canada
Aliment Pharmacol Ther 17:1481-91. 2003..Uninvestigated dyspepsia is common in family practice. The prevalence of clinically significant upper gastrointestinal findings (CSFs) in adult uninvestigated dyspepsia patients, and their predictability based on history, is unknown...
- Gastrointestinal stromal tumoursM Miettinen
Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC, USA
Ann Chir Gynaecol 87:278-81. 1998....
- Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptomsA N Wymenga
Department of Medical Oncology, University Hospital, Groningen, The Netherlands
J Clin Oncol 17:1111. 1999....
- Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported casesJun Soga
Niigata Seiryo University, Niigata, Japan
Cancer 103:1587-95. 2005..1-10.0 mm) tumors at a depth of invasion restricted to the mucosa and submucosa (sm carcinoids)...
- Mechanism of increased lipolysis in cancer cachexiaThorhallur Agustsson
Department of Surgery, Karolinska Institutet at Karolinska University Hospital, Stockhom, Sweden
Cancer Res 67:5531-7. 2007..The selective inhibition of this enzyme may prevent fat loss in cancer patients...
- Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysisEva Maria Duerr
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114, USA
Endocr Relat Cancer 15:243-56. 2008..This suggests that molecular profiling may enhance tumor classification schemes. Potential gene targets have also been identified, and PDGFR and RET are candidates that may represent novel therapeutic targets...
- Primary gastrointestinal non-Hodgkin's lymphoma. A population based study in central Finland in 1975-1993L Halme
Fourth Department of Surgery, Helsinki University Hospital, Finland
Acta Oncol 36:69-74. 1997..In conclusion the early distinction of gastrointestinal lymphomas is vital because of an increasing frequency of predisposing factors and a better prognosis due to new combination therapies...
- Molecular Strategies for Gastric Carcinoid SurgeryIrvin Modlin; Fiscal Year: 2005..A pre-operative determination of the neoplastic ECL cell gene expression relating to gastrin responsiveness will improve the rationale for therapeutic gastric or antral resection. ..
- TITLE OMMITTEDKenneth Wang; Fiscal Year: 2001..Endoscopic biopsies are routinely obtained from gastrointestinal neoplasms but two major problems have prevented their utilization for molecular analysis...
- Partner-Assisted Emotional Disclosure for GI CancerLaura Porter; Fiscal Year: 2006..If successful, it may enlarge our repertoire of methods for effectively increasing social support and enhancing the well being of both cancer patients and their partners. ..
- Dectection of occult mediastinal lymph node mestastasesMichael Wallace; Fiscal Year: 2007..In the R33 component of the grant application these criteria will be prospectively evaluated and correlated with clinical outcome in a second, larger cohort of patients. ..
- Randomized Trial of EUS Neurolysis in Pancreas CancerMichael Wallace; Fiscal Year: 2006..The primary outcome will be a reduction in pain at 1 month. Secondary outcomes will include the durability of pain control, quality of life, narcotic use and narcotic side effects. [unreadable] [unreadable]..
- Natural Killer Dendritic Cells in Listeria InfectionRonald DeMatteo; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Palliative Oxygen for the Relief of BreathlessnessAmy Abernethy; Fiscal Year: 2007..The results will also advance a long-standing international debate about the role of palliative oxygen for intractable dyspnea and it's funding. [unreadable] [unreadable] [unreadable]..
- Creation and demonstration of a palliative care research cooperative groupJean S Kutner; Fiscal Year: 2010....
- International Symposium on Cancer Metastasis and the Lymphovascular SystemSTANLEY LEONG; Fiscal Year: 2007..unreadable] [unreadable] [unreadable] [unreadable]..
- Molecular strategies to define carcinoids and rationalize surgical interventionIrvin Modlin; Fiscal Year: 2009..This will provide novel biological information and provide molecular data to identify occult metastasis predict spread and facilitate preemptive appropriate therapy. ..
- STI571 Therapy for Gastrointestinal Stromal TumorsRonald DeMatteo; Fiscal Year: 2002..The results are essential to advance our understanding of GIST biology and determine the therapeutic value and limitations of STI571. ..
- Enhanced Smoking Cessation for University StudentsAlexander V Prokhorov; Fiscal Year: 2010..It will set the stage for a randomized, controlled trial of the smoking prevention and cessation methods among this high-risk population. ..
- Novel Signaling Targets in GI Neuroendocrine TumorsHerbert Chen; Fiscal Year: 2005..The possibility that raf-l-mediated hormone suppression could be induced by a soluble factor would provide a plausible, therapeutic delivery method. ..
- Epidemiology of Syndromic GI Stromal TumorsJudy Ellen Garber; Fiscal Year: 2010..Our goal is to define the spectrum of syndromic GISTs, and to generate the information that will form the basis for clinical counseling for members of GIST kindreds, with and without germline mutations in KIT or PDGFRA. ..
- Antitumor Activity of Inducible Nitric Oxide SynthaseKeping Xie; Fiscal Year: 2005..Collectively, all of these insightful studies will be crucial to effectively targeting the iNOS/NO pathway in designing novel therapeutic strategies or improving current therapeutic modalities against cancer. ..
- PHENOTYPIC AND PSYCHOSOCIAL STUDY OF THE L1307K MUTATIONHenry Lynch; Fiscal Year: 2004....
- Metal Carcinogenesis: New ConceptsAnatoly Zhitkovich; Fiscal Year: 2006..unreadable] [unreadable] [unreadable] [unreadable]..
- Endothelial Nitric Oxide Synthase & Portal HypertensionVijay Shah; Fiscal Year: 2002..abstract_text> ..
- Structure, Process and Outcomes in Cancer SurgeryJohn D Birkmeyer; Fiscal Year: 2010..We will then identify the resources and processes of care that account for differences in hospital outcomes, with the ultimate goal of identifying best practices and improving care in all settings. ..
- Geographic Variation of Breast Cancer SurvivalMario Schootman; Fiscal Year: 2006..The findings of the proposed study will identify geographic disparities in survival and factors responsible, which can be used to develop and implement future interventions to reduce these disparities. [unreadable] [unreadable]..
- Folate-Genome Interactions in Colorectal CancerPATRICK STOVER; Fiscal Year: 2007..The long-term goal of this project is: (1). to determine the mechanism whereby alterations in folate metabolism influence cancer risk. ..
- CatheterScope for Intraluminal Image of Early.NeoplasiaEric Seibel; Fiscal Year: 2006..abstract_text> ..
- Caregiver Coping Skills training for Lung CancerFrancis Keefe; Fiscal Year: 2006..The proposed study rigorously evaluations methods for enhancing the effects of caregiver-assisted coping skills training in cancer patients and their caregivers. ..
- FUNCTION AND REGULATION OF GASTRINTimothy Wang; Fiscal Year: 2008..Overall, these studies will attempt to define the role of progastrin-derived peptides in stem cell regulation and in bridging genetic pathways in colorectal cancer. ..
- Phase II Clinical Trial Utilizing Lithium for Patients with Neuroendocrine TumorsHerbert Chen; Fiscal Year: 2008..Besides surgery, there are limited curative and palliative treatments available to patients with metastatic NE tumors, emphasizing the need for development of other forms of therapy. [unreadable] [unreadable] [unreadable]..
- Sensitivity Mechanisms in Chromium ToxicityAnatoly Zhitkovich; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Neighborhood effects on Quality of Life in Breast CancerMario Schootman; Fiscal Year: 2009..g., individual and neighborhoods simultaneously) using a multi-pronged approach to improve QoL, as recently recommended by the Institute of Medicine. ..
- Surveillance for Hepatocellular Carcinoma among HCV-infected VeteransHashem El Serag; Fiscal Year: 2009..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..
- Regulating Neuroendocrine Phenotype in CancerHerbert Chen; Fiscal Year: 2010..Furthermore, these finding may permit development of components of raf-1 pathway as therapeutic targets in the treatment and palliation of NE tumors. ..
- Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma Gary K Schwartz; Fiscal Year: 2010..Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule. ..
- Signaling Pathways in Medullary Thyroid CancerHerbert Chen; Fiscal Year: 2004..abstract_text> ..
- Gene Expression in Barrett's EsophagusHashem El Serag; Fiscal Year: 2006..We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays. ..
- Parenchymal/Stem Cell Pathways for Salivary Gland RepairRobert Redman; Fiscal Year: 2003..abstract_text> ..
- TRANSGENIC MOUSE MODELS OF PANCREATIC EXOCRINE FUNCTIONROBERT DE LISLE; Fiscal Year: 2003..That over expresses Muclin in the pancreatic acinar cell using the rat elastase promoter to direct cell specific expression. ..
- PATHOGENEISIS OF CYSTIC FIBROSIS IN THE GI SYSTEMROBERT DE LISLE; Fiscal Year: 2003..Pathology and Muclin expression will be compared in CF mice, and CF mice crossed with gastrin deficient mice (lack gastric acid secretion) to normalize intestinal Ph. ..
- Symposium on Cancer Metastasis and Lymphovascular SystemSTANLEY LEONG; Fiscal Year: 2004..abstract_text> ..
- ANXIETY, DEPRESSION, AND NONCARDIAC CHEST PAINFrancis Keefe; Fiscal Year: 2005..This study may lead to major advances in our understanding of non-cardiac chest pain and enlarge our repertoire of methods for effectively treating non-cardiac chest pain. ..
- MENTORING FOR NEW CANCER THERAPEAUTICSGary Schwartz; Fiscal Year: 2005..This K24 award mechanism represents the essence of what we are proposing and for which support is needed. ..
- SPOUSE GUIDED PAIN MANAGEMENT TRAINING FOR CANCER PAINFrancis Keefe; Fiscal Year: 2002..This study may lead to major advances in our understanding of cancer pain that occurs at end-of-life and enlarge our repertoire of methods for effectively treating this pain. ..
- Fine Needle Aspiration Biopsy(FNAB) Needle DeviceVinod Shidham; Fiscal Year: 2002..Apart from the worldwide market, the potential market in United States alone should exceed $1,500,000 per year. ..
- MOLECULAR MECHANISMS OF ANTIMICROTUBULE AGENTSCharles Coltman; Fiscal Year: 2001..This study may lead to a better selection of patients for either combination therapy, leading to improved quality of care and clinical outcome. ..
- In Vivo Raman Spectroscopy of Barrett's EsophagusLouis Michel Wong Kee Song; Fiscal Year: 2005..abstract_text> ..
- Failure of FasL Mediated Pathways in Tumor AngiogenesisVijay Shah; Fiscal Year: 2006..These insights may lead to novel and effective therapeutic strategies that target this pathway to prevent angiogenesis, and thereby prevent colorectal tumor development growth and spread. ..
- Novel Insights into Gastric CancerLopa Mishra; Fiscal Year: 2003..The proposed workshop, entitled "Novel Insights into Gastric Cancer" will take place on October 3rd, 2003 at the Levy Center, Georgetown University, Washington, D.C. ..
- Noninvasive Monitoring Glutathione Metabolism in TumorsMICHAEL GAMCSIK; Fiscal Year: 2010..abstract_text> ..
- Growth Factors, Curcumin and Colon CarcinogenesisPomila Singh; Fiscal Year: 2010..The results of these studies are expected to help in developing mechanism-based strategies for preventative/treatment protocols for CRCusing curcumin like agents. ..
- Spatial, Temporal, Social Disparities in Breast CancerMario Schootman; Fiscal Year: 2010....
- Stem Cells and Gastric CancerTIMOTHY CRAGIN WANG; Fiscal Year: 2010....
- Curbing Tobacco Use in Suburban and Rural SchoolsAlexander V Prokhorov; Fiscal Year: 2010..The study will be a group-randomized, controlled trial with 2000 participants aged 14-16 years from 16 high schools in suburban and rural southeast Texas. Follow-up assessments will be conducted at 6 weeks and at 6, 12, and 18 months. ..
- Experimentally Validated Mathematical Modeling of Oncolytic Virus InfectionWOLFGANG KORN; Fiscal Year: 2009..However, the results of these studies will be applicable to other types of cancer, thus potentially contribute to improving the treatment outcome for many cancer patients in the future. ..
- Process & Outcomes of BRCAL/2 clinical testingJudy Garber; Fiscal Year: 2003..The information learned from this project may help to create a standard for the optimal conduct of BRCA 1/2 testing, and potentially for other predisposition testing as well. ..
- End of Life Communication Skills for Oncology FellowsAnthony Back; Fiscal Year: 2005..This program will create a formal curriculum for communication skills that could be replicated in many institutions to improve the quality of oncologists-patient communication--and ultimately the quality of cancer care--nationwide. ..
- Healthcare Team Approach to Tobacco CessationAlexander Prokhorov; Fiscal Year: 2005..Also, to encourage and facilitate health care provider outreach in the community. AIM 5: To evaluate the proposed tobacco cessation counseling strategies for their costs and benefits. ..
- The Perception of Cancer Risk in Patients with Barrett's EsophagusNicholas Shaheen; Fiscal Year: 2007..The resultant study application will assess health-related quality of life, health-related anxiety and healthcare utilization as outcomes. [unreadable] [unreadable]..
- TRANSCRIPTIONAL CONTROL OF GASTRINJuanita Merchant; Fiscal Year: 2007..For type specifications, see instructions on page 6.) RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page 1 Description, ..
- Molecular Mechanisms of Portal HypertensionVijay Shah; Fiscal Year: 2007..abstract_text> ..
- Phase I Trial of Safingol and CisplatinGary Schwartz; Fiscal Year: 2006..conduct "proof of principle" biological assays to measure the degree of ceramide production and/or S1P inhibition, either of which may be predictive of clinical outcome or toxicity. ..
- Integral activity of the p53 family and its role in progression of colon tumorsAlexander Zaika; Fiscal Year: 2008..This information may provide new avenues for the development of novel prognostic and therapeutic targets. [unreadable] [unreadable] [unreadable]..
- FASEB Summer Conference: Folate, B12 and 1C MetabolismPATRICK STOVER; Fiscal Year: 2004..Similarly, the poster sessions also highlight the activities and needs of the younger participants. ..
- TGF-BETA REGULATION OF INTESTINAL EPITHELIAL CELLSJohn Barnard; Fiscal Year: 2009..abstract_text> ..
- 14th International Symposium on Regulatory PeptidesTimothy Wang; Fiscal Year: 2002..abstract_text> ..
- Capturing cancer cells with peptide bead technologyDerick Lau; Fiscal Year: 2003..The development of this technology will greatly enhance our ability of diagnosing malignant pleural effusion, and it will provide a model for capturing and expanding exfoliated malignant cells in other body fluids. ..
- THE ROLE OF MYCOBACTERIA IN CROHN'S DISEASEDavid Graham; Fiscal Year: 2005..The results of this study should either confirm or refute the proposed etiologic association of M. paratuberculosis and Crohn's disease as well as the identification of patients with Crohn's disease and M. paratuberculosis. ..
- BREAST CANCER SYMPOSIUMCharles Coltman; Fiscal Year: 2003..Abstracts accepted for presentation are published in the journal Breast Cancer Research and Treatment. All symposia to date have been granted Category 1, AMA credit for continuing education. ..